BNT327 20 mg ml, BNT327 50 mg ml, PEMBROLIZUMAB
CA2660002
Phase 3 small_molecule active
Quick answer
BNT327 20 mg ml, BNT327 50 mg ml, PEMBROLIZUMAB for Non-Small Cell Lung Cancer is a Phase 3 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active